Real‑world data in elderly men from Yokosuka City 15 years after introducing prostate‑specific antigen‑based population screening.

Nirei,Takuma; Tabei,Tadashi; Sakai,Naoki; Koh,Hideshige; Yoshida,Minoru; Fujikawa,Atsushi; Ito,Hiroki; Tsutsumi,Sohgo; Furuhata,Souichi; Noguchi,Sumio; Taguri,Masataka; Kobayashi,Kazuki

doi:10.3892/mco.2021.2471

Real‑world data in elderly men from Yokosuka City 15 years after introducing prostate‑specific antigen‑based population screening.

Authors:
- Takuma Nirei
- Tadashi Tabei
- Naoki Sakai
- Hideshige Koh
- Minoru Yoshida
- Atsushi Fujikawa
- Hiroki Ito
- Sohgo Tsutsumi
- Souichi Furuhata
- Sumio Noguchi
- Masataka Taguri
- Kazuki Kobayashi
View Affiliations

Affiliations: Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Kanagawa 238‑8558, Japan, Department of Urology, Wakakusa Hospital, Yokohama, Kanagawa 236‑8653, Japan, Department of Urology, Yokosuka City Uwamachi Hospital, Yokosuka, Kanagawa 238‑8567, Japan, Department of Urology, Kinugasa Hospital, Yokosuka, Kanagawa 238‑8588, Japan, Department of Urology, Yokosuka City Hospital, Yokosuka, Kanagawa 240‑0195, Japan, Furuhata Hinyokika Clinic, Yokosuka, Kanagawa 238‑0031, Japan, Satomi Jin‑Hinyokika Clinic, Yokosuka, Kanagawa 238‑0007, Japan, Department of Data Science, School of Data Science, Yokohama City University, Yokohama, Kanagawa 236‑0027, Japan
Published online on: December 20, 2021 https://doi.org/10.3892/mco.2021.2471
Article Number: 38
Copyright: © Nirei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mass screening based on prostate‑specific antigen (PSA) reduces mortality in prostate cancer. However, the effectiveness of this screening in the elderly has not been demonstrated. In the city of Yokosuka, Japan, PSA screening has been conducted since 2001 and the present study examined the real‑world status of PSA‑based population screening in the elderly. It retrospectively evaluated 1,117 prostate cancer patients >75 years of age. The patients were divided into two groups: The screened group comprising patients diagnosed by PSA‑based population screening or workplace screening and PSA follow‑up patients at urology clinics; and the non‑screened group comprising patients detected by other methods. Overall survival (OS), cancer‑specific survival (CSS) and factors contributing to shorter CSS between the groups were compared. In patients >75 years of age, the screened group had significantly longer OS (171 vs. 154 months; P=0.019) and CSS (median not reached; P=0.020) but screening was not an independent factor associated with prolonged OS or CSS on multivariate analysis. The factors contributing to shorten CSS in the elderly were ≥T3 (odds ratio: 3.301 [1.704‑6.369], P<0.001), M1 (odds ratio: 4.856 [2.809‑8.393], P<0.001) and Gleason score ≥8 (odds ratio: 4.691 [2.479‑8.876], P<0.001). In those with metastasis, PSA screening was not associated with prolonged OS or CSS. Real‑world data 15 years after introducing PSA‑based population screening was not an independent factor for both OS and CSS in multivariate analyses for patients >75 years of age.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.PubMed/NCBI View Article : Google Scholar
2	Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:909–916. 1987.PubMed/NCBI View Article : Google Scholar
3	Mistry K and Cable G: Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 16:95–101. 2003.PubMed/NCBI View Article : Google Scholar
4	Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schäfer G, Frauscher F, Schennach H and Bartsch G: Prostate-specific antigen testing in Tyrol, Austria: Prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health. 57:57–62. 2012.PubMed/NCBI View Article : Google Scholar
5	Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, et al: ERSPC Investigators. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 384:2027–2035. 2014.PubMed/NCBI View Article : Google Scholar
6	Aus G, Bergdahl S, Lodding P, Lilja H and Hugosson J: Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur Urol. 51:659–664. 2007.PubMed/NCBI View Article : Google Scholar
7	Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH and Steyerberg EW: Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam). Int J Cancer. 127:2639–2644. 2010.PubMed/NCBI View Article : Google Scholar
8	Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL and Andriole GL: Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 123:592–599. 2017.PubMed/NCBI View Article : Google Scholar
9	Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC and Berg C: Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 7:303–311. 2010.PubMed/NCBI View Article : Google Scholar
10	Shoag JE, Mittal S and Hu JC: Reevaluating PSA testing rates in the PLCO trial. N Engl J Med. 374:1795–1796. 2016.PubMed/NCBI View Article : Google Scholar
11	Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, Lane JA, Noble S, Oliver SE, Evans S, et al: CAP Trial Group: Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial. JAMA. 319:883–895. 2018.PubMed/NCBI View Article : Google Scholar
12	Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H and Melnikow J: Prostate-specific antigen-based screening for prostate cancer: Evidence report and systematic review for the US Preventive Services Task Force. JAMA. 319:1914–1931. 2018.PubMed/NCBI View Article : Google Scholar
13	Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T and Dahm P: Prostate cancer screening with prostate-specific antigen (PSA) test: A systematic review and meta-analysis. BMJ. 362(k3519)2018.PubMed/NCBI View Article : Google Scholar
14	Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, et al: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 71:618–629. 2017.PubMed/NCBI View Article : Google Scholar
15	Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, et al: NCCN clinical practice guidelines prostate cancer early detection, version 2.2015. J Natl Compr Canc Netw. 13:1534–1561. 2015.PubMed/NCBI View Article : Google Scholar
16	Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebell M, Epling JW Jr, Kemper AR, et al: US Preventive Services Task Force: Screening For Prostate Cancer: US preventive services task force recommendation statement. JAMA. 319:1901–1913. 2018.PubMed/NCBI View Article : Google Scholar
17	Mok Y, Kimm H, Shin SY, Jee SH and Platz EA: Screening prostate-specific antigen concentration and prostate cancer mortality: The Korean Heart Study. Urology. 85:1111–1116. 2015.PubMed/NCBI View Article : Google Scholar
18	Liu Y, Xiao G, Zhou JW, Yang JK, Lu L, Bian J, Zhong L, Wei QZ, Zhou QZ, Xue KY, et al: Optimal starting age and baseline level for repeat tests: Economic concerns of psa screening for chinese men - 10-year experience of a single center. Urol Int. 104:230–238. 2020.PubMed/NCBI View Article : Google Scholar
19	Sakai N, Taguri M, Kobayashi K, Noguchi S, Ikeda S, Koh H, Satomi Y and Furuhata A: Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means. Int J Urol. 22:747–752. 2015.PubMed/NCBI View Article : Google Scholar
20	Okihara K, Kitamura K, Okada K, Mikami K, Ukimura O and Miki T: Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int J Urol. 15:156–161. 2008.PubMed/NCBI View Article : Google Scholar
21	Ito K, Kakehi Y, Naito S and Okuyama A: Japanese Urological Association. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol. 15:763–768. 2008.PubMed/NCBI View Article : Google Scholar
22	Tabei T, Taguri M, Sakai N, Koh H, Yosida M, Fujikawa A, Nirei T, Tsutsumi S, Ito H, Furuhata S, et al: Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening. Prostate. 80:824–830. 2020.PubMed/NCBI View Article : Google Scholar
23	Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 40:373–383. 1987.PubMed/NCBI View Article : Google Scholar
24	Rebbeck TR and Haas GP: Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol. 21:7496–7506. 2014.PubMed/NCBI
25	Bell KJ, Del Mar C, Wright G, Dickinson J and Glasziou P: Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer. 137:1749–1757. 2015.PubMed/NCBI View Article : Google Scholar